ANGEN Stock Overview
Anatolia Tani ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.S., a biotechnology company, engages in the design, development, and manufacture of real-time PCR kits, nucleic acid extraction kits, and automated nucleic acid extraction instruments in Turkey.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
Anatolia Tani ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.S. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₺13.58 |
| 52 Week High | ₺21.76 |
| 52 Week Low | ₺9.23 |
| Beta | -0.22 |
| 1 Month Change | 6.18% |
| 3 Month Change | 0.37% |
| 1 Year Change | 0.30% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 9.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| ANGEN | TR Biotechs | TR Market | |
|---|---|---|---|
| 7D | -1.6% | -2.9% | -2.8% |
| 1Y | 0.3% | -24.7% | 113.8% |
Return vs Industry: ANGEN exceeded the TR Biotechs industry which returned -26.4% over the past year.
Return vs Market: ANGEN underperformed the TR Market which returned 112.1% over the past year.
Price Volatility
| ANGEN volatility | |
|---|---|
| ANGEN Average Weekly Movement | 4.5% |
| Biotechs Industry Average Movement | 7.7% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in TR Market | 11.8% |
| 10% least volatile stocks in TR Market | 5.5% |
Stable Share Price: ANGEN has not had significant price volatility in the past 3 months.
Volatility Over Time: ANGEN's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 171 | n/a | www.anatoliageneworks.com |
Anatolia Tani ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.S., a biotechnology company, engages in the design, development, and manufacture of real-time PCR kits, nucleic acid extraction kits, and automated nucleic acid extraction instruments in Turkey. It offers microbiology, genetic disorder, panel, sequencing, and food testing kits; and manual spin column and magnetic bead nucleic acid extraction kits, and automated NA extraction instrument kits. The company provides products for diseases, such as brucellosis, chlamydia trachomatis, cytomegalovirus, crimean-congo hemorrhagic fever, novel coronavirus (2019-NCoV)/SARS-CoV-2, epstein-barr virus, hepatitis B, hepatitis C, hepatitis D, herpes simplex virus, human immunodeficiency virus, human papillomavirus, JC and BK polyomaviruses, malaria, measles, meningitis, respiratory infection, parvovirus B19, torque teno virus, toxoplasmosis, tuberculosis, ureaplasma, and west nile virus diseases, as well as factor II, factor V leiden, and methylene-tetra-hydro-folate-reductase mutation diseases.
Anatolia Tani ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.S. Fundamentals Summary
| ANGEN fundamental statistics | |
|---|---|
| Market cap | ₺2.99b |
| Earnings (TTM) | ₺122.57m |
| Revenue (TTM) | ₺163.74m |
24.4x
P/E Ratio18.2x
P/S RatioIs ANGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANGEN income statement (TTM) | |
|---|---|
| Revenue | ₺163.74m |
| Cost of Revenue | ₺45.97m |
| Gross Profit | ₺117.77m |
| Other Expenses | -₺4.80m |
| Earnings | ₺122.57m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.56 |
| Gross Margin | 71.92% |
| Net Profit Margin | 74.86% |
| Debt/Equity Ratio | 0.1% |
How did ANGEN perform over the long term?
See historical performance and comparison